HELP

Helus Pharma Inc.

Nasdaq· Pharmaceutical Preparations· Inc. A6· CIK 0001833141 Biotech & Drug Discovery

$10.69 +0.50 (+4.92%)

Oct 26 4:00 PM ET · prev $10.19

Market cap

$767.1M

Small cap

Consensus

Buy

86% Buy or better · 7 analysts

Median target

🔒 Subscribers only

1 year

+64.2%

from $6.51 · Oct 27

30 days

−15.1%

from $12.59

52-week range

$3.87–14.02

−24% from high · low Jun 10

Avg volume 20D

1.43M

shares / day

Short interest

3.46M

≈4.7% of shares · +7.4%

Days to cover

1.7

at average volume

Insider net

+$38.7K

1 buyer · 0 sellers · 12 mo

New fund stakes

Q2 2026 13F · 0 exits

Reddit crowd

50°

Neutral · 3 mentions this week

SecBot read MIXED 21 reports · 90 days

Balance 0 bearish · 2 bullish · 19 neutral oldest → newest, height = score

Avg score

·High conf. 17/21

Strongest NEUTRAL Helus Pharma provided a clinical program update via an investor presentation, reiterating that topline data…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

R Mar 5 Helus Pharma announced positive topline results from a Phase 2 signa…
R Jun 29 Cybin Inc. (HELP) reported fiscal year 2026 financial results showin…
E Jul 21 FDA: Helus Pharma Completes Enrollment in Phase 3 APPROACH Stud…
R Aug 14 Helus Pharma reported Q4 fiscal 2026 (period ended March 31, 2026) E…
A Sep 18 Barclays initiates
E Sep 21 FDA: Helus Pharma Presents New Analyses on HLP003 in Major Depr…
B Sep 29 1 insider buy $38.7K at $12.91
E Oct 15 Offering: Helus Pharma Appoints Dr. Suresh Durgam to Board of Direct…

Signal stack

Where each data set points today.

InsidersBULLISH

1 insider bought $38.7K at an average $12.91. No open-market sales. Price is 17% below their cost.
InstitutionsMIXED

Q2 2026: 8 added (0 new), 8 trimmed or exited.
AnalystsBULLISH

6 of 7 rate it Buy or better.
EstimatesRISING

Current-quarter EPS estimate −$1.071 → −$1.010 over 90 days. 0 up, 1 down in 30 days.
Short sellersSTEADY

Short interest +7.4% to 3.46M shares. 1.7 days to cover, ≈4.7% of shares.
TrendDOWNTREND

11% below its 50-day average.
SocialQUIET

Crowd 50° (neutral) this week from 3 mentions: 0 bullish, 0 bearish. No setup call.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
ADAGE CAPITAL PARTNERS GP, L.L.C.	DOUBLED	3,060,000	$20.2M
CITADEL ADVISORS LLC	TRIM	620,959	$4.1M
MORGAN STANLEY	TRIM	461,886	$3.1M
JANE STREET GROUP, LLC	DOUBLED	280,903	$1.9M
JPMORGAN CHASE & CO	DOUBLED	237,828	$1.6M
ROYCE & ASSOCIATES LP	ADD	232,078	$1.5M
HRT FINANCIAL LP	TRIM	124,658	$823.0K
Point72 Asset Management, L.P.	DOUBLED	106,457	$703.7K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

7 analysts

Buy 86% rate it Buy or better

Strong Buy2Buy4Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access

Recent actions

Date	Firm	Action	Rating
Oct 22, 2026	Wells Fargo MAINTAIN	MAINTAIN	Overweight
Sep 18, 2026	Barclays INITIATE	INITIATE	Overweight
Aug 20, 2026	TD Cowen MAINTAIN	MAINTAIN	Buy
Jul 27, 2026	Wells Fargo INITIATE	INITIATE	Overweight
Jul 9, 2026	HC Wainwright & Co. MAINTAIN	MAINTAIN	Buy
Jul 1, 2026	Canaccord Genuity MAINTAIN	MAINTAIN	Buy

Insider ledger

Form 4

$38.7K

bought · 1 insider

sold · 0 insiders

−17.2%

vs their $12.91 cost

Date	Insider	Type	Value
Sep 30, 2026	Glavine Paul Chief Growth Officer	AWARD	248,000 sh
Sep 30, 2026	So Eric H. L. Director	AWARD	248,000 sh
Sep 29, 2026	Cavers Greg Chief Financial Officer	BUY	$38.7K

Earnings setup

Estimates

−$1.01

EPS estimate, this quarter

+6%

estimate change, 90 days

0↑ 1↓

revisions, 30 days

Current-quarter EPS estimate

−$1.071

90d

−$0.945

60d

−$0.945

30d

−$0.948

−$1.010

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	-$1.01	-$1.30–-$0.58	-6.9%	$0.00
Next Q	-$0.95	-$1.33–-$0.58	-7.9%	$0.00
Current FY	-$4.10	-$5.55–-$2.90	-10.7%	$0.00
Next FY	-$2.47	-$3.04–-$1.90	+2.8%	$11.8M